A systematic review of the role of human papillomavirus testing within a cervical screening programme.

[1]  T. Sasagawa,et al.  Human Papillomavirus Infection and Risk Determinants for Squamous Intraepithelial Lesion and Cervical Cancer in Japan , 1997, Japanese journal of cancer research : Gann.

[2]  A. Iwamoto,et al.  Amplification and typing of multiple cervical cancer‐associated human papillomavirus DNAS using a single pair of primers , 1990, International journal of cancer.

[3]  J. Cuzick,et al.  Human papillomavirus testing in primary cervical screening , 1995, The Lancet.

[4]  M. Parsonage,et al.  Discounting and health benefits. , 1992, Health economics.

[5]  M A Koopmanschap,et al.  Economic aspects of cervical cancer screening. , 1990, Social science & medicine.

[6]  S Gallivan,et al.  Can papilloma virus testing be used to improve cervical cancer screening? , 1996, International journal of cancer.

[7]  J. Habbema,et al.  Predicting mortality from cervical cancer after negative smear test results , 1993, British medical journal.

[8]  A. Reingold,et al.  Genital human papillomavirus infection in female university students as determined by a PCR‐based method , 1991, JAMA.

[9]  L. Mango,et al.  Interactive Neural Network–Assisted Screening , 1998, Acta Cytologica.

[10]  M J Buxton,et al.  Modelling in economic evaluation: an unavoidable fact of life. , 1997, Health economics.

[11]  Michael Pidd,et al.  Tools for Thinking—Modelling in Management Science , 1997 .

[12]  N. Waugh,et al.  Costs and benefits of cervical screening. III. Cost/benefit analysis of a call of previously unscreened women , 1996, Cytopathology : official journal of the British Society for Clinical Cytology.

[13]  J D Habbema,et al.  Cervical‐cancer screening: Attendance and cost‐effectiveness , 1990, International journal of cancer.

[14]  M. Fahs,et al.  Cost Effectiveness of Cervical Cancer Screening for the Elderly , 1992, Annals of Internal Medicine.

[15]  Mathematical models and natural history in cervical cancer screening. , 1986, IARC scientific publications.

[16]  T. Kirchhoff,et al.  Repeated evaluation of human papillomavirus 16 status in cervical swabs of young women with a history of normal Papanicolaou smears , 1992, Obstetrics and gynecology.

[17]  J. Cuzick,et al.  Type-specific human papillomavirus DNA in abnormal smears as a predictor of high-grade cervical intraepithelial neoplasia. , 1994, British Journal of Cancer.

[18]  W. Lancaster,et al.  Amplification of human papillomavirus DNA sequences by using conserved primers , 1989, Journal of clinical microbiology.

[19]  J. Habbema,et al.  Rescreen Effect in Conventional and PAPNET Screening , 1998, Acta Cytologica.

[20]  B. Johansson,et al.  Human papillomavirus findings in relation to cervical intraepithelial neoplasia grade: a study on 476 Stockholm women, using PCR for detection and typing of HPV. , 1997, Human pathology.

[21]  F. Skjeldestad,et al.  Treatment of pre‐invasive conditions during opportunistic screening and its effectiveness on cervical cancer incidence in one Norwegian county , 1997, International journal of cancer.

[22]  C. Meijer,et al.  Analysis of cytomorphologically abnormal cervical scrapes for the presence of 27 mucosotropic human papillomavirus genotypes, using polymerase chain reaction , 1994, International journal of cancer.

[23]  J. Habbema,et al.  Epidemiological evidence for age-dependent regression of pre-invasive cervical cancer. , 1991, British Journal of Cancer.

[24]  S. Gallivan,et al.  Evaluating cervical cancer screening programmes for developing countries , 1997, International journal of cancer.

[25]  J D Habbema,et al.  Model building on the basis of Dutch cervical cancer screening data. , 1985, Maturitas.

[26]  D M Parkin,et al.  An evaluation of screening policies for cervical cancer in England and Wales using a computer simulation model. , 1986, Journal of epidemiology and community health.

[27]  E. Knox.  Ages and frequencies for cervical cancer screening. , 1976, British Journal of Cancer.

[28]  N. Waugh,et al.  Costs and benefits of cervical screening. II. Is it worthwhile reducing the screening interval from 5 to 3 years? , 1996, Cytopathology : official journal of the British Society for Clinical Cytology.

[29]  S Gallivan,et al.  Cytological screening and management of abnormalities in prevention of cervical cancer: an overview with stochastic modelling. , 1994, Journal of clinical pathology.

[30]  D M Eddy,et al.  The frequency of cervical cancer screening. Comparison of a mathematical model with empirical data , 1987, Cancer.

[31]  D. Eddy.  Screening for cervical cancer. , 1990, Annals of internal medicine.

[32]  D. Gyrd-Hansen,et al.  A cost-effectiveness analysis of cervical cancer screening: health policy implications. , 1995, Health policy.

[33]  H. Adami,et al.  Natural history of cervical neoplasia: consistent results obtained by an identification technique. , 1989, British Journal of Cancer.

[34]  M. Weinstein,et al.  Recommendations of the Panel on Cost-effectiveness in Health and Medicine , 1997 .

[35]  J D Habbema,et al.  Duration of preclinical cervical cancer and reduction in incidence of invasive cancer following negative pap smears. , 1995, International journal of epidemiology.

[36]  M. Husain,et al.  Should cervical cytologic testing be augmented by cervicography or human papillomavirus deoxyribonucleic acid detection? , 1991, American journal of obstetrics and gynecology.

[37]  D. Nash.  Problems and Progress in Medical Care , 1969 .

[38]  Human papillomavirus testing by hybrid capture appears to be useful in triaging women with a cytologic diagnosis of atypical squamous cells of undetermined significance. , 1995, American journal of obstetrics and gynecology.

[39]  J. Habbema,et al.  Present evidence on the value of HPV testing for cervical cancer screening: a model-based exploration of the (cost-)effectiveness. , 1997, British Journal of Cancer.

[40]  D. Parkin.  A computer simulation model for the practical planning of cervical cancer screening programmes. , 1985, British Journal of Cancer.

[41]  T A Sheldon,et al.  Discounting in health care decision-making: time for a change? , 1992, Journal of public health medicine.

[42]  M. Evander,et al.  Human papillomavirus infection is transient in young women: a population-based cohort study. , 1995, The Journal of infectious diseases.

[43]  Julian Peto,et al.  Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide Perspective , 1995 .

[44]  J Cairns,et al.  Discounting and health benefits: another perspective. , 1992, Health economics.

[45]  H. Adami,et al.  Cytologic screening for cancer of the uterine cervix in Sweden evaluated by identification and simulation. , 1990, British Journal of Cancer.

[46]  C B Schechter,et al.  Cost-effectiveness of rescreening conventionally prepared cervical smears by PAPNET testing. , 1996, Acta cytologica.

[47]  J. Habbema,et al.  Preventive Pap-smears: balancing costs, risks and benefits. , 1992, British Journal of Cancer.

[48]  A. Miller,et al.  Optimising the age, number of tests, and test interval for cervical screening in Canada. , 1982, Journal of epidemiology and community health.